



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/662,651
Source: 01PE
Date Processed by STIC: 9/25/2003

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Raw Sequence Listing Error Summary

ERROR DETECTED SUGGESTED CORRECTION SERIAL NUMBER: 10/662,651

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1 Wrapped Nucleic
Wrapped Aminos The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."

2 Invalid Line Length The rules require that a line **not exceed** 72 characters in length. This includes white spaces.

3 Misaligned Amino
Numbering The numbering under each 5th amino acid is misaligned. **Do not use tab codes between numbers; use space characters**, instead.

4 Non-ASCII The submitted file was **not saved** in ASCII(DOS) text, as required by the Sequence Rules. Please **ensure your subsequent submission is saved in ASCII text**.

5 Variable Length Sequence(s) _____ contain n's or Xaa's representing more than one residue. **Per Sequence Rules, each n or Xaa can only represent a single residue**. Please present the **maximum number** of each residue having variable length and indicate in the <220>-<223> section that some may be missing.

6 PatentIn 2.0
"bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. **This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences**.

7 Skipped Sequences
(OLD RULES) Sequence(s) _____ missing. If intentional, please insert the following lines for **each** skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.

8 Skipped Sequences
(NEW RULES) Sequence(s) _____ missing. If intentional, please insert the following lines for **each** skipped sequence.
<210> sequence id number
<400> sequence id number
000

9 Use of n's or Xaa's
(NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is **MANDATORY** if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

10 Invalid <213>
Response Per 1.823 of Sequence Rules, the only **valid** <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is **required** when <213> response is Unknown or is Artificial Sequence

11 Use of <220> Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses.
Use of <220> to <223> is **MANDATORY** if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)

12 PatentIn 2.0
"bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

13 Misuse of n/Xaa "n" can **only** represent a single nucleotide; "Xaa" can **only** represent a single amino acid

nothing else



OIPE

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/10/662,651

DATE: 09/25/2003
 TIME: 16:18:16

Input Set : A:\Seq listing.txt
 Output Set: N:\CRF4\09252003\J662651.raw

3 <110> APPLICANT: De Strooper, Bart
 4 Annaert, Wim
 6 <120> TITLE OF INVENTION: Binding Domains Between Presenilins and Their Substrates as
 7 Targets for Drug Screening
 9 <130> FILE REFERENCE: 2676-6086US
 C--> 11 <140> CURRENT APPLICATION NUMBER: US/10/662,651
 C--> 11 <141> CURRENT FILING DATE: 2003-09-15
 11 <150> PRIOR APPLICATION NUMBER: PCT/EP/02/043033
 12 <151> PRIOR FILING DATE: 2002-03-15
 14 <150> PRIOR APPLICATION NUMBER: EP01201015.3
 15 <151> PRIOR FILING DATE: 2001-03-16
 17 <160> NUMBER OF SEQ ID NOS: 22
 19 <170> SOFTWARE: PatentIn version 3.2
 21 <210> SEQ ID NO: 1
 22 <211> LENGTH: 21
 23 <212> TYPE: PRT
 24 <213> ORGANISM: Artificial
 26 <220> FEATURE:
 27 <223> OTHER INFORMATION: Human transmembrane region 1 of presenilin 1
 29 <400> SEQUENCE: 1
 31 Val Ile Met Leu Phe Val Pro Val Thr Leu Cys Met Val Val Val
 32 1 5 10 15
 35 Ala Thr Ile Lys Ser
 36 20
 39 <210> SEQ ID NO: 2
 40 <211> LENGTH: 21
 41 <212> TYPE: PRT
 42 <213> ORGANISM: Artificial
 44 <220> FEATURE:
 45 <223> OTHER INFORMATION: Human transmembrane region 1 of presenilin 2
 47 <400> SEQUENCE: 2
 49 Val Ile Met Leu Phe Val Pro Val Thr Leu Cys Met Ile Val Val Val
 50 1 5 10 15
 53 Ala Thr Ile Lys Ser
 54 20
 57 <210> SEQ ID NO: 3
 58 <211> LENGTH: 8
 59 <212> TYPE: PRT
 60 <213> ORGANISM: Artificial
 62 <220> FEATURE:
 63 <223> OTHER INFORMATION: carboxy-terminal of human presenilin 1
 65 <400> SEQUENCE: 3
 67 Leu Ala Phe His Gln Phe Tyr Ile

Does Not Comply
 Corrected Diskette Needed
 pp 3-4

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/662,651

DATE: 09/25/2003

TIME: 16:18:16

Input Set : A:\Seq listing.txt

Output Set: N:\CRF4\09252003\J662651.raw

68 1 5
71 <210> SEQ ID NO: 4
72 <211> LENGTH: 8
73 <212> TYPE: PRT
74 <213> ORGANISM: Artificial
76 <220> FEATURE:
77 <223> OTHER INFORMATION: carboxy-terminal of human presenilin 2
79 <400> SEQUENCE: 4
81 Leu Ala Ser His Gln Leu Tyr Ile
82 1 5
85 <210> SEQ ID NO: 5
86 <211> LENGTH: 11
87 <212> TYPE: PRT
88 <213> ORGANISM: Artificial
90 <220> FEATURE:
91 <223> OTHER INFORMATION: Part of the transmembrane region of human APP
93 <400> SEQUENCE: 5
95 Thr Val Ile Val Ile Thr Leu Val Met Leu Lys
96 1 5 10
99 <210> SEQ ID NO: 6
100 <211> LENGTH: 5
101 <212> TYPE: PRT
102 <213> ORGANISM: Artificial
104 <220> FEATURE:
105 <223> OTHER INFORMATION: Part of the transmembrane region of telencephalin
107 <400> SEQUENCE: 6
109 Val Ala Gly Pro Trp
110 1 5
113 <210> SEQ ID NO: 7
114 <211> LENGTH: 34
115 <212> TYPE: PRT
116 <213> ORGANISM: Artificial
118 <220> FEATURE:
119 <223> OTHER INFORMATION: synthesized peptide
122 <220> FEATURE:
123 <221> NAME/KEY: SITE
124 <222> LOCATION: (19)..(34)
125 <223> OTHER INFORMATION: conserved transmembrane region
127 <400> SEQUENCE: 7
129 Val Val Ile Ala Thr Val Ile Val Ile Thr Leu Val Met Leu Lys Lys
130 1 5 10 15
133 Lys Gln Cys Arg Gln Leu Arg Ile Ala Gly Arg Arg Leu Arg Gly Arg
134 20 25 30
137 Ser Arg
141 <210> SEQ ID NO: 8
142 <211> LENGTH: 18
143 <212> TYPE: PRT
144 <213> ORGANISM: Artificial
146 <220> FEATURE:

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/662,651

DATE: 09/25/2003
TIME: 16:18:16

Input Set : A:\Seq listing.txt
Output Set: N:\CRF4\09252003\J662651.raw

147 <223> OTHER INFORMATION: synthesized peptide
 149 <400> SEQUENCE: 8
 151 Val Val Ile Ala Thr Val Ile Val Ile Thr Leu Val Met Leu Lys Lys
 152 1 5 10 15
 155 Lys Gln
 159 <210> SEQ ID NO: 9
 160 <211> LENGTH: 17
 161 <212> TYPE: PRT
 162 <213> ORGANISM: Artificial
 164 <220> FEATURE:
 165 <223> OTHER INFORMATION: synthesized peptide
 168 <220> FEATURE:
 169 <221> NAME/KEY: misc_feature
 170 <222> LOCATION: (1)..(1)
 171 <223> OTHER INFORMATION: X is a palmitoyl group
 173 <400> SEQUENCE: 9
 W--> 175 Xaa Leu Val Gln Pro Phe Met Asp Gln Leu Ala Phe His Gln Phe Tyr
 176 1 5 10 15
 179 Ile
 183 <210> SEQ ID NO: 10
 184 <211> LENGTH: 32
 185 <212> TYPE: PRT
 186 <213> ORGANISM: Artificial
 188 <220> FEATURE:
 189 <223> OTHER INFORMATION: synthesized peptide
 192 <220> FEATURE:
 193 <221> NAME/KEY: SITE
 194 <222> LOCATION: (1)..(16)
 195 <223> OTHER INFORMATION: conserved transmembrane region
 197 <400> SEQUENCE: 10
 199 Gly Arg Gln Leu Arg Ile Ala Gly Arg Arg Leu Arg Gly Arg Ser Arg
 200 1 5 10 15
 203 Leu Val Gln Pro Phe Met Asp Gln Leu Ala Phe His Gln Phe Tyr Ile
 204 20 25 30
 207 <210> SEQ ID NO: 11
 208 <211> LENGTH: 16
 209 <212> TYPE: PRT
 210 <213> ORGANISM: Artificial
 212 <220> FEATURE:
 213 <223> OTHER INFORMATION: synthesized peptide
 215 <400> SEQUENCE: 11
 217 Leu Val Gln Pro Phe Met Asp Gln Leu Ala Phe His Gln Phe Tyr Ile
 218 1 5 10 15
 221 <210> SEQ ID NO: 12
 222 <211> LENGTH: 31
 223 <212> TYPE: PRT
 224 <213> ORGANISM: Artificial
 226 <220> FEATURE:
 227 <223> OTHER INFORMATION: synthesized peptide

see item 13 on Error
summary
sheet

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/662,651

DATE: 09/25/2003
TIME: 16:18:16

Input Set : A:\Seq listing.txt
Output Set: N:\CRF4\09252003\J662651.raw

230 <220> FEATURE:
231 <221> NAME/KEY: SITE
232 <222> LOCATION: (16)..(31)
233 <223> OTHER INFORMATION: conserved transmembrane region
235 <400> SEQUENCE: 12
237 Ala Thr Val Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Gly
238 1 5 10 15
241 Arg Gly Leu Arg Ile Ala Gly Arg Arg Leu Arg Gly Arg Ser Arg
242 20 25 30
245 <210> SEQ ID NO: 13
246 <211> LENGTH: 15
247 <212> TYPE: PRT
248 <213> ORGANISM: Artificial
250 <220> FEATURE:
251 <223> OTHER INFORMATION: synthesized peptide
253 <400> SEQUENCE: 13
255 Ala Thr Val Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln
256 1 5 10 15
259 <210> SEQ ID NO: 14
260 <211> LENGTH: 9
261 <212> TYPE: PRT
262 <213> ORGANISM: Artificial
264 <220> FEATURE:
265 <223> OTHER INFORMATION: synthesized peptide
268 <220> FEATURE:
269 <221> NAME/KEY: misc_feature
270 <222> LOCATION: (1)..(1)
271 <223> OTHER INFORMATION: X is a palmitoyl group
273 <400> SEQUENCE: 14
W--> 275 xaa Leu Ala Phe His Gln Phe Tyr Ile 13
276 1 5
279 <210> SEQ ID NO: 15
280 <211> LENGTH: 13
281 <212> TYPE: PRT
282 <213> ORGANISM: Artificial
284 <220> FEATURE:
285 <223> OTHER INFORMATION: synthesized peptide
288 <220> FEATURE:
289 <221> NAME/KEY: misc_feature
290 <222> LOCATION: (1)..(1)
291 <223> OTHER INFORMATION: X is a palmitoyl group
293 <400> SEQUENCE: 15
W--> 295 xaa Phe Met Asp Gln Leu Ala Phe His Gln Phe Tyr Ile
296 1 5 10
299 <210> SEQ ID NO: 16
300 <211> LENGTH: 24
301 <212> TYPE: PRT
302 <213> ORGANISM: Artificial
304 <220> FEATURE:

same entry

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/662,651

DATE: 09/25/2003
TIME: 16:18:16

Input Set : A:\Seq listing.txt
Output Set: N:\CRF4\09252003\J662651.raw

305 <223> OTHER INFORMATION: synthesized peptide
308 <220> FEATURE:
309 <221> NAME/KEY: SITE
310 <222> LOCATION: (1)..(16)
311 <223> OTHER INFORMATION: conserved transmembrane region
313 <400> SEQUENCE: 16
315 Gly Arg Gln Leu Arg Ile Ala Gly Arg Arg Leu Arg Gly Arg Ser Arg
316 1 5 10 15
319 Leu Ala Phe His Gln Phe Tyr Ile
320 20
323 <210> SEQ ID NO: 17
324 <211> LENGTH: 28
325 <212> TYPE: PRT
326 <213> ORGANISM: Artificial
328 <220> FEATURE:
329 <223> OTHER INFORMATION: synthesized peptide
332 <220> FEATURE:
333 <221> NAME/KEY: SITE
334 <222> LOCATION: (1)..(16)
335 <223> OTHER INFORMATION: conserved transmembrane region
337 <400> SEQUENCE: 17
339 Gly Arg Gln Leu Arg Ile Ala Gly Arg Arg Leu Arg Gly Arg Ser Arg
340 1 5 10 15
343 Phe Met Asp Gln Leu Ala Phe His Gln Phe Tyr Ile
344 20 25
347 <210> SEQ ID NO: 18
348 <211> LENGTH: 8
349 <212> TYPE: PRT
350 <213> ORGANISM: Artificial
352 <220> FEATURE:
353 <223> OTHER INFORMATION: synthesized peptide
355 <400> SEQUENCE: 18
357 Leu Ala Phe His Gln Phe Tyr Ile
358 1 5
361 <210> SEQ ID NO: 19
362 <211> LENGTH: 12
363 <212> TYPE: PRT
364 <213> ORGANISM: Artificial
366 <220> FEATURE:
367 <223> OTHER INFORMATION: synthesized peptide
369 <400> SEQUENCE: 19
371 Phe Met Asp Gln Leu Ala Phe His Gln Phe Tyr Ile
372 1 5 10
375 <210> SEQ ID NO: 20
376 <211> LENGTH: 16
377 <212> TYPE: PRT
378 <213> ORGANISM: Artificial
380 <220> FEATURE:
381 <223> OTHER INFORMATION: synthesized peptide

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/662,651

DATE: 09/25/2003
TIME: 16:18:17

Input Set : A:\Seq listing.txt
Output Set: N:\CRF4\09252003\J662651.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:9; Xaa Pos. 1
Seq#:14; Xaa Pos. 1
Seq#:15; Xaa Pos. 1

Invalid <213> Response:

Use of "Artificial" only as "<213> Organism" response is incomplete, per 1.823(b) of New Sequence Rules. Valid response is Artificial Sequence.

Seq#:1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22

VERIFICATION SUMMARY
PATENT APPLICATION: **US/10/662,651**

DATE: 09/25/2003
TIME: 16:18:17

Input Set : **A:\Seq listing.txt**
Output Set: **N:\CRF4\09252003\J662651.raw**

L:11 M:270 C: Current Application Number differs, Replaced Current Application No
L:11 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:175 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:0
L:275 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14 after pos.:0
L:295 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15 after pos.:0